)
Visual
test
Entrada Therapeutics
Entrada Therapeutics (TRDA) investor relations material
Entrada Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic pipeline progress and expansion
Advancing four clinical-stage programs in Duchenne muscular dystrophy (DMD) with data readouts expected in Q2 and Q4 2026 for ENTR-601-44, and mid-2026 for ENTR-601-45.
Expansion into ocular diseases with the nomination of ENTR-801 for Usher syndrome type 2A and plans for a second candidate in 2026.
Partnership with Vertex on myotonic dystrophy type 1 (DM1) progressing, with global Phase 1/2 study enrollment and dosing to complete mid-2026.
Pipeline includes ongoing discovery in neuromuscular, ocular, and undisclosed disease areas.
Financial runway extends into Q3 2027, supporting continued R&D and expansion.
Clinical and scientific differentiation
EEV platform enables 25-fold improvement in endosomal escape, leading to higher muscle concentrations at lower doses compared to antibody-based therapies.
Optimized PMO sequences and satellite cell uptake are expected to drive functional benefit and safety.
Healthy volunteer studies showed zero treatment-related adverse events and strong target engagement.
Lower drug load reduces risk of antibody response and manufacturing burden.
Data from ENTR-601-44 expected to de-risk subsequent DMD programs due to shared EEV technology.
Regulatory and commercialization strategy
Ex-U.S. clinical strategy accelerates data collection and supports U.S. FDA accelerated approval pathway.
ELEVATE 44-201 study designed to support U.S. accelerated approval and global registration.
Targeting over 14,000 DMD patients in the U.S. and Europe with multiple exon-skipping therapies.
Ocular program aims for clinically relevant exon skipping and favorable dosing intervals.
Ongoing efforts to expand into metabolic, CNS, and other undisclosed indications.
Explain the low-dose advantage over antibody therapies
What early ENTR-801 data supports favorable dosing?
How is kidney liability mitigated for Entrada's oligos?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebWASH
Q4 2025 net income up 48%, adjusted EPS up 41%, AUA $7.8B, dividend yield 7.58%. - 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
Next Entrada Therapeutics earnings date
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb, 2026
Entrada Therapeutics
Next Entrada Therapeutics earnings date
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular sites traditionally considered unreachable by conventional therapies. The company's proprietary Endosomal Escape Vehicle technology facilitates the efficient intracellular delivery of diverse therapeutic modalities, including RNA, antibodies, and enzymes. This approach is being applied to develop treatments for a range of diseases, particularly in neuromuscular, ocular, metabolic, and immunological areas. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage